Skip to main content

VIX ETPs (VXX, UVXY, SVXY)

Updated Jun 24, 2026 at 2:35pm

Research Draft Medium 1,170 words

VIX exchange-traded products (ETPs) are the most accessible way for an ordinary equity-account holder to take a position on volatility — but they are widely misunderstood and have a reputation as wealth-destroyers. The central tension is that they do not track the VIX spot index. They track a rolling basket of VIX futures, and because the VIX futures curve is upward-sloping (in contango) the large majority of the time, long products like VXX and UVXY bleed value continuously, while inverse products like SVXY harvest that same bleed at the cost of rare but catastrophic drawdown risk. They are trading instruments for short horizons, not portfolio insurance to buy and hold.

How they're structured

All three reference the S&P 500 VIX Short-Term Futures Index, which holds the front two VIX futures months and rebalances daily to a constant weighted-average maturity of roughly 30 days (Barclays/ProShares fact sheets). The index sells a slice of the expiring front-month contract and buys the second month every day — the "roll."

  • VXX — iPath Series B S&P 500 VIX Short-Term Futures ETN, issued by Barclays (incepted Jan 2018; the original 2009 VXX matured in Jan 2019). It targets 1x daily exposure. Critically, VXX is an ETN — senior unsecured debt of Barclays, carrying issuer credit risk, not a fund holding actual futures. Investor fee ~0.89%/yr (Barclays fact sheet).
  • UVXY — ProShares Ultra VIX Short-Term Futures ETF, +1.5x daily, structured as a fund (commodity pool) holding futures.
  • SVXY — ProShares Short VIX Short-Term Futures ETF, −0.5x daily (inverse, half-leverage).

UVXY and SVXY reset their leverage daily, so multi-day returns compound and can diverge substantially from the headline multiple — ProShares' own prospectus warns multi-day results "may be significantly different" from the daily target.

How they're used in practice

  • Short-term hedging / event bets (VXX, UVXY): buying ahead of a feared shock (Fed decision, earnings-heavy week, geopolitical risk) for a sharp negative-beta payoff. VIX and equities are strongly negatively correlated, so a long-vol ETP spikes when the S&P falls. UVXY's 1.5x adds convexity for a smaller dollar outlay.
  • Premium / contango harvesting (SVXY, or shorting VXX/UVXY): collecting the roll yield in calm markets. Selling/shorting the long products or holding inverse SVXY profits from the persistent decay.
  • Options on the ETPs: UVXY and VXX have liquid, heavily traded options. Many practitioners prefer defined-risk option structures (put spreads on UVXY to play decay, call spreads to play a spike) precisely because the underlyings move so violently. Shorting the shares outright carries theoretically unlimited risk on a spike.

These are tactical instruments measured in days to a few weeks, not core holdings.

Adoption, debate & evidence

The structural-decay problem is not folklore — it is well documented. The VIX futures curve is in contango the substantial majority of trading days (commonly cited at roughly 75–85% historically; e.g., Six Figure Investing's curve data), producing a persistent negative roll yield for long holders. Academic work (e.g., Whaley and later studies on VIX ETPs) finds these products carry high negative expected returns and that adding direct VIX ETPs to an S&P 500 portfolio deteriorates risk-adjusted returns rather than improving them, despite the VIX index itself being a good diversifier — the futures-roll cost is what destroys the benefit.

Reported decay magnitudes for long products are large but should be treated as regime-dependent rather than precise constants: commentary commonly cites long VIX ETPs losing on the order of half their value or more per year in calm regimes from roll cost and compounding. The flip side: inverse strategies can produce strong returns for long stretches — until they don't.

Volmageddon (Feb 5, 2018) is the defining cautionary tale. The VIX rose ~115% that day (Cboe / CFA Institute), its largest one-day jump on record. Credit Suisse's XIV (−1x inverse ETN) lost ~97% and was terminated; ProShares' SVXY fell ~91% (CFA Institute Financial Analysts Journal, 2021). The mechanical cause: inverse products must buy VIX futures into a rising market to rebalance, and the forced buying near the 4:00 PM settlement window created a feedback loop the futures market couldn't absorb. In response, ProShares cut SVXY from −1x to −0.5x and UVXY from 2x to 1.5x, effective late February 2018. The current −0.5x SVXY is deliberately less fragile than the XIV that blew up — a vital point: SVXY today is not the same risk profile as the products that detonated in 2018.

Strengths & limitations

When they work: as short-duration tactical tools. Long products deliver explosive, immediate negative-beta payoffs during genuine shocks; inverse/short positions are a clean way to monetize the well-established variance risk premium in calm markets.

When they fail: held for weeks-plus, long products bleed relentlessly via roll cost and volatility decay regardless of being "right" on direction over time. Inverse products face left-tail ruin — a single volatility spike can erase years of gains overnight, and daily-reset leverage means decay also harms inverse holders during choppy, non-trending vol.

The #1 misuse: treating VXX/UVXY as buy-and-hold "crash insurance." The roll cost makes them a wasting asset; an investor can be correct that a crash is coming yet still lose money waiting. The mirror-image misuse is treating SVXY/short-vol as a free yield engine while ignoring its fat left tail. Additional caveats: VXX's ETN/credit-risk structure, leverage-change and early-termination clauses in the prospectus, and tax complexity (commodity-pool K-1 issues vary by product).

Sources

Disputed / qualified: Precise annual-decay figures (e.g., "−50% to −80%/yr") and the exact share of days in contango (~75–85%) are regime-dependent and vary by source and window — treated here as commonly-cited ranges, not fixed constants.